Recent Updates
Recently added Catalysts
INKT Positive Sentiment Score: 75/100

MiNK Therapeutics to Participate in September Investor Conferences

Thursday, August 24, 2023 1 min read
Key Takeaway: MiNK Therapeutics, a clinical-stage biopharma company focused on iNKT cell therapies, announced its participation in two upcoming investor conferences in September 2023. CEO Dr. Jennifer Buell will be presenting at the Baird 2023 Global Healthcare Conference on September 12 and at the HC Wainwright 25th Annual Global Investment Conference on September 13. The events will provide opportunities for the company to showcase its innovative approach to cancer and immune-mediated disease treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • MiNK Therapeutics is active in engaging investors through conferences.
  • Participation may enhance visibility and interest in iNKT therapies.
  • Dr. Jennifer Buell's presence emphasizes leadership commitment.

Full Press Release Details

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, Chief Executive Officer and President, will participate in the following upcoming investor conferences:
Baird 2023 Global Healthcare Conference – Fireside chat will be held in-person on Tuesday, September 12th, 2023, at 12:15 p.m. ET, in New York, NY.
HC Wainwright 25th Annual Global Investment Conference – Fireside chat will be held in-person on Wednesday, September 13th, 2023, at 2:30 p.m. ET, in New York, NY. A live webcast and replay will be accessible on the Events and Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations.
About MiNK Therapeutics
investor@minktherapeutics.com
communications@minktherapeutics.com

Frequently Asked Questions

What is MiNK Therapeutics focused on?

MiNK Therapeutics specializes in developing allogeneic off-the-shelf iNKT cell therapies.

Who is participating in the upcoming investor conferences?

Dr. Jennifer Buell, CEO and President, will participate in the conferences.

When is the Baird 2023 Global Healthcare Conference?

The conference is scheduled for September 12th, 2023, at 12:15 p.m. ET.

How can I view the HC Wainwright conference webcast?

The webcast will be available on the Events and Presentations page of their website.

What type of diseases does MiNK Therapeutics target?

The company aims to treat cancer and other immune-mediated diseases.

Tags: INKT Viatris Investor Conferences Healthcare MiNK Therapeutics iNKT therapies investor conferences clinical-stage cancer treatment
Last updated: Aug 24, 2023